Lupin Launches Dapagliflozin And Metformin Hydrochloride Extended-Release Tablets In US Market

Lupin Ltd, a leading Indian pharmaceutical company, has introduced Dapagliflozin and Metformin Hydrochloride extended-release tablets in the US. The combination therapy is widely prescribed for type 2 diabetes, offering improved glycemic control and patient convenience.

Product Significance

The launch enhances Lupin’s product offerings in the US, one of its largest markets. Dapagliflozin, an SGLT2 inhibitor, combined with Metformin, provides a dual mechanism to lower blood sugar levels, reduce cardiovascular risks, and improve treatment outcomes.

Market Impact

With diabetes prevalence rising globally, Lupin’s entry into this therapeutic segment strengthens its competitive positioning. The launch is expected to contribute significantly to revenue growth while reinforcing Lupin’s commitment to affordable healthcare solutions in regulated markets.

Key Highlights

• Lupin launches Dapagliflozin + Metformin ER tablets in US
• Targets type 2 diabetes management with dual therapy
• Expands generics portfolio in regulated markets
• Strengthens presence in US pharmaceutical sector
• Supports global fight against diabetes with affordable solutions

Sources: Business Standard, Economic Times, Mint, Company Announcements